CNBC
19 Aug 2026, 10:46 UTC · 1h ago
Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
CNBC
19 Aug 2026, 10:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
A personalized mRNA cancer vaccine from Merck and Moderna met its primary goals in a Phase 3 trial, significantly extending recurrence-free survival for high-risk melanoma patients compared to Keytruda alone. — Positive late-stage trial results for a new treatment class are major catalysts for biotech valuations and potential future revenue streams.
+0.80The trial results validate a personalized treatment approach targeting unique tumor mutations, which the companies are now testing across other cancers like lung, bladder, and renal cell carcinoma. — Success in melanoma provides a proof-of-concept that could expand the addressable market to several other major cancer types.
+0.60The treatment combination reduced the risk of cancer spreading to distant parts of the body and was reported to be well tolerated by patients. — Strong safety and efficacy profiles increase the probability of FDA approval and clinical adoption.
+0.40Continue reading
6 related stories
Top 2 movers · tap to explore
While initial data is positive, Merck and Moderna have not yet specified a timeline for submitting applications for U.S. regulatory approval. — Lack of a concrete filing timeline creates uncertainty regarding when the product will actually reach the commercial market.
-0.20Which stocks this story touches
The company's stock jumped over 10% following successful late-stage trial results for its mRNA-based personalized cancer vaccine.
Positive phase three trial results for a personalized cancer vaccine combination involving Keytruda led to a stock price increase.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
